254 related articles for article (PubMed ID: 31338935)
21. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Kim S; Han SJ; Kim DJ; Lee KW; Kim HJ
J Diabetes Res; 2018; 2018():5246976. PubMed ID: 29850606
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.
Savarese G; Perrone-Filardi P; D'Amore C; Vitale C; Trimarco B; Pani L; Rosano GM
Int J Cardiol; 2015 Feb; 181():239-44. PubMed ID: 25528528
[TBL] [Abstract][Full Text] [Related]
23. Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study.
Baksh S; Wen J; Mansour O; Chang HY; McAdams-DeMarco M; Segal JB; Ehrhardt S; Alexander GC
Sci Rep; 2021 Aug; 11(1):16637. PubMed ID: 34404825
[TBL] [Abstract][Full Text] [Related]
24. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Seong JM; Kim JJ; Kim HJ; Sohn HS
Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
Lee H; Chung HJ; Pawar A; Patorno E; Kim DH
JAMA Dermatol; 2020 Oct; 156(10):1107-1114. PubMed ID: 32697283
[TBL] [Abstract][Full Text] [Related]
26. Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D; Carstensen B; Elisabetta P; Lanzinger S; Tan EC; Yabe D; Kim DJ; Sheu WH; Melzer-Cohen C; Holl RW; Núñez J; Ha KH; Halvorsen S; Langslet G; Karasik A; Nyström T; Niskanen L; Guleria S; Klement R; Carrasco M; Foersch J; Shay C; Koeneman L; Hoti F; Farsani SF; Khunti K; Zaccardi F; Subramanian A; Nirantharakumar K; ;
Cardiovasc Diabetol; 2023 Aug; 22(1):233. PubMed ID: 37653496
[TBL] [Abstract][Full Text] [Related]
27. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
28. Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.
Fu AZ; Johnston SS; Ghannam A; Tsai K; Cappell K; Fowler R; Riehle E; Cole AL; Kalsekar I; Sheehan J
Diabetes Care; 2016 May; 39(5):726-34. PubMed ID: 26740636
[TBL] [Abstract][Full Text] [Related]
29. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
Santamarina M; Carlson CJ
BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
[TBL] [Abstract][Full Text] [Related]
30. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
Yu OH; Yin H; Azoulay L
Can J Diabetes; 2015 Oct; 39(5):383-9. PubMed ID: 25840943
[TBL] [Abstract][Full Text] [Related]
31. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
[No Abstract] [Full Text] [Related]
32. Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease.
Rhee JJ; Han J; Montez-Rath ME; Kim SH; Cullen MR; Stafford RS; Winkelmayer WC; Chertow GM
Diabetes Obes Metab; 2022 May; 24(5):928-937. PubMed ID: 35118793
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
Dawwas GK; Smith SM; Park H
Diabetes Obes Metab; 2019 Jan; 21(1):28-36. PubMed ID: 30039524
[TBL] [Abstract][Full Text] [Related]
34. Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis.
Kadowaki T; Sarai N; Hirakawa T; Taki K; Iwasaki K; Urushihara H
Diabetes Obes Metab; 2018 Dec; 20(12):2830-2839. PubMed ID: 29974673
[TBL] [Abstract][Full Text] [Related]
35. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
Lee SJ; Ha KH; Lee JH; Lee H; Kim DJ; Kim HC
PLoS One; 2019; 14(2):e0211959. PubMed ID: 30742667
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
Patorno E; Goldfine AB; Schneeweiss S; Everett BM; Glynn RJ; Liu J; Kim SC
BMJ; 2018 Feb; 360():k119. PubMed ID: 29437648
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular events and mortality among type 2 diabetes mellitus patients newly prescribed first-line blood glucose-lowering drugs monotherapies: A population-based cohort study in the Catalan electronic medical record database, SIDIAP, 2010-2015.
Herrera Comoglio R; Vidal Guitart X
Prim Care Diabetes; 2021 Apr; 15(2):323-331. PubMed ID: 33248925
[TBL] [Abstract][Full Text] [Related]
38. Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study.
Giorda CB; Picariello R; Tartaglino B; Marafetti L; Di Noi F; Alessiato A; Costa G; Gnavi R
BMJ Open; 2015 Jun; 5(6):e007959. PubMed ID: 26048211
[TBL] [Abstract][Full Text] [Related]
39. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
[TBL] [Abstract][Full Text] [Related]
40. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease.
Tan X; Liang Y; Rajpura JR; Yedigarova L; Noone J; Xie L; Inzucchi S; de Havenon A
Cardiovasc Diabetol; 2023 Nov; 22(1):319. PubMed ID: 37985992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
